达拉图穆马
医学
重症监护医学
立场文件
流行病学
多发性骨髓瘤
肿瘤科
内科学
家庭医学
病理
硼替佐米
作者
Corrado Girmenia,Michèle Cavo,Alessandro Corso,Francesco Di Raimondo,Pellegrino Musto,Massimo Offidani,Maria Teresa Petrucci,Antonio Rosato,Giovanni Barosi
标识
DOI:10.1016/j.critrevonc.2022.103623
摘要
Daratumumab is approved for newly diagnosed or relapsed/refractory multiple myeloma (MM). The use of daratumumab has improved patient outcomes but has changed the frequency and epidemiology of infections. However, the optimal approach to prophylaxis and supportive therapy for daratumumab-emergent infections is unknown and represents an unmet clinical need in MM. Consequently, an expert panel convened to compose recommendations for optimal infection control in patient candidates to or under daratumumab treatment for MM. Scientific evidence on infections secondary to daratumumab was evaluated, and a consensus was developed by group discussion for key questions selected according to the clinical relevance. The following key issues were addressed: infectious risk assessment and risk stratification, infection mitigation strategies, and management of infectious complications in patients with MM treated with daratumumab.
科研通智能强力驱动
Strongly Powered by AbleSci AI